Sherlock Biosciences Chosen as a 2020 Red Herring Top 100 North America Winner
Cambridge, Mass., November 20, 2020 – Sherlock Biosciences, an Engineering Biology company dedicated to making diagnostic testing better, faster and more affordable, has been chosen as a winner of Red Herring’s Top 100 North America award, one of the technology industry’s most prestigious prizes. Red Herring announced the winners of its Top 100 North America 2020 event yesterday, recognizing the continent’s most exciting and innovative private technology companies.
The winners have been chosen from thousands of entrants, whittled down to hundreds presenting their companies at the virtual conference on November 17th and 18th. The event, led by Red Herring chairman Alex Vieux, included two days of keynote speeches, discussions and finalist presentations.
“The Sherlock team is honored to be chosen as a winner of the Red Herring Top 100 award. This award recognizes our team’s ability to create the best solutions for diagnostic testing that will be performed wherever testing is needed.” said Rahul Dhanda, co-founder, president and CEO of Sherlock Biosciences. “As we continue to develop products to address COVID-19 and more, we look forward to additional milestones that will improve global health.”
Industry experts, insiders and journalists on a wide variety of criteria including financial performance, innovation, business strategy, and market penetration judged companies. Winners ran the gamut of verticals, from FinTech and Artificial Intelligence to Security, IoT, and many more industries.
Red Herring’s editors have been evaluating the world’s startups and tech companies for over two decades. It gives them the ability to see through the industry’s hype to pick firms that will continue on a trajectory to success. Brands such as Alibaba, Kakao, Skype, Spotify, Twitter and YouTube have all been singled out in Red Herring’s storied history.
“2020’s crop of Top 100 winners has been among our most intriguing yet,” said Vieux. “North America has led the way in tech for so many years, and to see such unique, pioneering entrepreneurs and companies here, which is in many ways the heartland of the industry, has been a thrilling experience.
“What has excited me most is to see so many people forging niches in high-tech and cutting edge sectors,” added Vieux. “Some of the technical wizardry and first-rate business models showcased at the conference has been fantastic to learn about. We believe Sherlock Biosciences embodies the drive, skill and passion on which tech thrives. Sherlock should be proud of its achievement – the competition was incredibly strong.”
About Sherlock Biosciences
Sherlock Biosciences is dedicated to making molecular diagnostics better, faster and more affordable through Engineering Biology platforms. The company is developing applications of SHERLOCK™, a CRISPR-based method to detect and quantify specific genetic sequences, and INSPECTR™, a Synthetic Biology-based molecular diagnostics platform that is instrument-free. SHERLOCK and INSPECTR can be used in virtually any setting without complex instrumentation, opening up a wide range of potential applications in areas including precision oncology, infection identification, food safety, at-home tests, and disease detection in the field. In May 2020, the company received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Sherlock™ CRISPR SARS-CoV-2 kit, the first FDA-authorized use of CRISPR technology. For more information visit Sherlock.bio.
Contact
Katie Engleman, 1AB
katie@1abmedia.com